АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология

Желудочно-кишечные

Прочитайте:
  1. ДРУГИЕ ЗАБОЛЕВАНИЯ, ВЫЗЫВАЮЩИЕ ОСТРЫЕ ЖЕЛУДОЧНО-КИШЕЧНЫЕ КРОВОТЕЧЕНИЯ
  2. Желудочно-кишечные заболевания
  3. Желудочно-кишечные кровотечения
  4. Желудочно-кишечные кровотечения
  5. Некоторые желудочно-кишечные гормоны
  6. ОСТРЫЕ ЖЕЛУДОЧНО-КИШЕЧНЫЕ КРОВОТЕЧЕНИЯ ОПУХОЛЕВОЙ ЭТИОЛОГИИ

Инфаркт или резекция кишки (ниже двенадцатиперстной кишки), селезёнки, печени или жёлчного пузыря, когда-либо, по любым причинам (счёт 2, если более, чем в одном месте) Мезентериальная недостаточность Хронический перитонит

Стриктуры или хирургические операции на верхней части ЖКТ, когда-либо

Мышечно-скелетные Мышечная атрофия или слабость

Деформирующий или арозивный артрит (включая вправимые деформации, исключая аваскулярные некрозы) Остеопороз с переломами или коллапсом позвонков (исключая аваскулярный некроз) Аваскуляриый некроз (счёт 2, если >1) Остеомиелит

Кожные

Рубцующаяся хроническая алопеция Обширное рубцевание или панникулит (кроме скальпа и подушечек пальцев)


1(2)

1(2)

1(2)

1(2)


160 ♦ Ревматология ♦ Системная красная волчанка

Окончание табл. 3

 

   
Изъязвление кожи (исключая тромбоз) в течение более 6 мес Преждевременная недостаточность гонад Сахарныйдиабет (вне зависимости от терапии) Малигнизация(исключая дисплазию) (счёт 2, если более одной локализации) 1 1 1 1(2)

ЛИТЕРАТУРА

\.Abu-ShakraM., UrowitzM.B., Gladman D.D., GoughJ. Mortality studies in systemic lupus erythematosus. Results from a single center//J. Rheumatol. - 1995. - Vol. 22. -P. 1265-1270.

I.Abu-ShakraM., UrowitzM.B., Gladman D.D., GoughJ. Mortality studies in systemic lupus erythematosus. Results from a single center//Ibid. - P. 1259-1264. 3. Al-Herz A., Schulzer M., Esdaile J.M. Survey of antimalarial use in lupus pregnancy and lactation // Ibid. - 2002. - Vol. 29. -P. 700.

4. Alarcon-SegoviaD., TumlinJ.,FurieR.A. et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythema­tosus: Results from a randomized, double blind, placebo controlled study // Arthri­tis Rheumatol. - 2003. - Vol. 48, N 2. -P. 442-454.

5. Alvarez-Nemegyei J., Cobarrubias-Co-
bos A., Escalante-Triay F. et al.
Bromo-
criptine in systemic lupus erythematosus: a
double-blind, randomized, placebo-cont­
rolled study // Lupus. - 1998. - Vol. 7. -
P. 414-419.

6. Appel A.E., Sablay L.B., Golden R.A. et
al.
The effect of normalization of serum
complement and anti-DNA antibody on the
course of lupus nephritis // Am. J. Med. -
1978. -Vol.64. - P. 274-283.

7. Austin H.A., Klippel J.K., Balow J.E. et
al.
Therapy of lupus nephritis // N. Engl. J.
Med. - 1986. - Vol. 314. - P. 614-619.

8. Austin H.A., Vaugham EM., Boumpas
D.T. et al.
Lupus membranous nephropathy:
Controlled trial of prednisone, pulse cyclo-
phosphamide and cyclosporine (abstract) //


J. Am. Soc. Nephrol. - 2000. - Vol. 11.-P. A439.

9. Baletta M., Sabella D., Magri P. et al.
Cyclosporin plus steroids versus steroids
alone in the treatment of lupus nephritis / Eds
Sessa, Meroni, Battini // Contrib. Nephrol.

- 1992. - Vol. 99. - R 129-136.

10. Bansal V.K., BeioJ.A. Treatment of lupus
nephritis, a meta-analysis of clinical trials//
Am. J. Kidney Dis. - 1997. - Vol. 29. -
R 193-199.

11. Barile L., Olguin L., Ariza R. et al.
Controlled clinical trial of cyclophosphamide
vs methylprednisolone in severe neurologic
manifestation in SLE // Arthritis Rheum
(Abstracts). -2001. -Vol.88.

12. Barile L.A., Jara L.J., Medina-
Rodriguez F. et al.
Pulmonary haemorrhage
in systemic lupus erythematosus // Lupus.

- 1997. -Vol.6. -P. 445-448.

13. Barile L, Lavatle С Transverse myelitis
in systemic lupus erythematosus. The effect
of IV pulse methylprednisolone and cyc­
lophosphamide//J. Rheumatol. - 1992. -
Vol. 19. - R 370.

14. Ben-CheritE., Putterman C.Naparstek
У.
Lupus refractory pleural effusion: transient
reasons to intravenous immunoglobulins //
Ibid. - 1991. - Vol. 18. - P. 1635-1637.

15. Bermas B.L, Hill J.A. Effects of immu-
nosuppressive drugs during pregnancy //
Arthritis Rheum. - 1995. - Vol. 38. -
R 1722.

16. Blanchetle V., Freedman J., Garvey B.
Management of chronic immune thrombo-
cytopenic purpura in children and adults //
Semin. Hematol. - 1998. - Vol. 35. -
Suppl. 1. - P. 36.

17. Boehm I.В., Boehm G.A., Bauer R.
Management of cutaneous lupus erythe-


matosus with low dose methotrexate: indi­cation for modulation of inflammatory mechanisms // Rheumatol. Int. — 1998. — Vol. 18. - P. 59-62.

18. BoletisJ.N., loannidisJ.P.A., Boki K.A.,
Moutsopoulos H.M.
Intravenous immuno-
globulin compared with cyclophosphamide
for proliferative lupus nephritis // Lancet. —
1999. - Vol. 354. - P. 569-570.

19. Bootsma H., Spronik P., Derksen R. et
al.
Prevention of relapses in systemic lupus
erythematosus//Ibid. - 1995. - Vol. 345.
- P. 1595-1599.

20. Boumpas D.T., Barez S., Klippel J.H.,
Balow J.E.
Intermittent cyclophosphamide
for the treatment of autoimmune thrombo-
cytopenia in systemic lupus erythematosus
//Ann. Intern. Med. - 1990. - Vol. 112.-
P. 674.

21. Boumpas D.T., Austin H.A., Vaughn
EM. et al.
Controlled trial of pulse methyl-
prednisolone versus two regimens of pulse
cyclophosphamide in severe lupus nephritis
// Lancet. - 1992. - Vol. 340. - P. 741-
745.

22. BoumpasD.T., FesslerB.J., Austin H.A.
Ill et al.
Systemic lupus erythematosus:
EmergingconceptsPart2: Dermatologicand
joint disease, the antiphospholipid antibody
syndrome, pregnancy and hormonal therapy,
morbidity and mortality, and pathogenesis //
Ann. Intern. Med. - 1995. - Vol. 123. -
P. 42.

23. Boumpas D.T., Patronas N.J., Dalakas
M.C. et al.
Acute transverse myelitis in
systemic lupus erythematosus: Magnetic
resonance imaging and review of the lite­
rature//J. Rheumatol. - 1990. - Vol. 17. -
P. 89.

24. Boumpas D.T., Yamada H., Patronas
N.J. et al.
Pulse cyclophosphamide for severe
neuropsychiatric lupus // Q. J. Med. —
1991. - Vol. 81, N 296. - P. 975-984.

25. Buchanan N.M.M., Toubi E..
Khamashta M.A. et al.
Hydroxychloroquine
and lupus pregnancy: review of a series of 36
cases // Ann. Rheum. Dis. - 1996. -
Vol. 55. - P. 486-488.

26. Cade R., Spooner G., Schlein E. et al.
Comparison of azathioprine, prednisone, and


Системная красная волчанка о 161

heparin alone or combined in treating lupus nephritis//Nephron. - 1973. - Vol. 10. -R 37-56.

27. Callen J.P., Spencer L.V., Bhatnagar
Burruss J. et al.
Azathioprine: an effective,
corticosteroid-sparing therapy for patients
with recalcitrant cutaneous lupus erythe­
matosus or with recalcitrant cutaneous
leukocytoclastic vasculitis // Arch. Der-
matol. - 1991. - Vol. 127. - P. 515-522.

28. Callen J.P. Treatment of cutaneous le­
sions in patients with lupus erythematosus //
Dermatol. Clin. - 1994. - Vol. 12. -
P. 201-206.

29. Carette S., Klippel J.H. Decker J.L. et al.
Controlled studies of role immunosuppres-
sive drugs in lupus nephritis // Ann. Intern.
Med. - 1983. - Vol. 99. - R 1 -8.

30. Carneiro J.R.M., Sato E. Double blind,
randomized, placebo controlled clinical trial
of methotrexate in systemic lupus erythe­
matosus // J. Rheumatol. — 1999. —
Vol.26. - R 1275-1279.

31. Cervera R., Khamashita M.A., Font J.
et al.
Morbidity and mortality in systemic
lupus erythematosus during a 5-year peri­
od // Medicine. - 1990. - Vol. 78. -
R 167-175.

32. Chan T.M., Li F.K., Hao W.K. et al.
Treatment of membranous lupus nephritis
with nephrotic syndrome by sequential
immunosuppression // Lupus. — 1999. —
Vol.8. -R 545-551.

33. Chan T.M., Li F.K., Tang C.S.O. et al.
Efficacy of mycophenolate mofetil in patients
with diffuse proliferalive lupus nephritis //
N. Engl. J. Med. - 2000. - Vol. 343. -
R 1156-1162.

M.ChangD.M.,LanJ.L.,LinH.Y.,LuoS.F. Dehydroepiandrosterone treatment of wo­men with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial // Arthritis Rheum. - 2002. - Vol. 46. -R 2942-2947.

35. Contreras G., Pardo V., Leclercq B. et al. Maintenance therapy for proliferative form of lupus nephritis: a randomized clinical trial comparing quarterly intravenous cyclophos­phamide versus oral mycophenolate mofetil


162 ♦ Ревматология ♦ Системная красная волчанка


or azathioprine (abstract) // J. Am. Soc. Nephrol. - 2002. - Vol. 13. - P. 15 A.

36. Corley C.CJr, LessnerH.E., Larsen W.E.
Azathioprine therapy of «autoimmune»
diseases//Am. J. Med. - 1966. -Vol.41. -
P. 404.

37. Costedoat-Chalumeau N., Amoura Z.,
Aymard G. et al.
Evidence of transplacental
passage of hydroxychloroquine in humans //
Arthritis Rheum. - 2002. - Vol. 46. -
P. 1123-1124.

38. CoulB.M., Williams L.S., Goldstein LB.
et al.
Anticoagulants and antiplatelet agents
in acute ischemic stroke. Report of the
joint stroke guideline develkpment com­
mittee of the American Academy of Neu­
rology and the American Stroke Association
(a Division of the American Heart Asso­
ciations)// Stroke. - 2002. - Vol. 33. - P.
1934-1942.

39. Cuadrado M.J. Treatment and monito­
ring of patients with antiphospholipid antibo­
dies and thrombotic history (Hughes synd­
rome)// Curr. Rheumatol. Rep. - 2002. -
Vol. 4. - P. 392.

40. D'Cruz D. Antimalarial therapy: a pa­
nacea for mild lupus? // Lupus. - 2001. -
Vol. 10.-P. 148-151.

41. D'Cruz D., Khamashta M., Hughes G.
Pulmonary manifestations of systemic lupus
erythematosus // Dubois' Lupus Erythema-
tosus. - 2002. - P. 663-683.

42. Derksen R.H.W.M., Hene R.J.,
Kallenberg C.G.M. et al.
Prospective multi-
center trial on the short term effect of plasma
exchange versus cytotoxic drugs in steroid
resistant lupus nephritis // Neth. J. Med. -
1988.-Vol.33.-P. 168-177.

43. Derksen H.W.M., Khamashta M.A.,
Branch D.W.
Management of the obstetric
antiphospholipid syndrome // Arthritis
Rheum. - 2004. - Vol. 50. - P. 1028-1039.

44. Dinanat H.J., Decker J.L., Klippel J.H.
et al.
Alternative modes of cyclophosphami-
de and azathioprine therapy in lupus
nephritis//Ann. Intern. Med. - 1982. -
Vol. 96. - R 728-736.

45. Donadio J.V., Holley K.E., Wagoner
R.D. et al.
Further observation on the treat­
ment of lupus nephritis with prednisone and


combined prednisone and azathioprine // Arthritis Rheum. - 1974. - Vol. 17. -R 573-581.

46. Donadio J.V., Holley K.E., Ferguson
R.H., llstrup D.M.
Treatment of diffuse
proliferative lupus nephritis with prednisone
and combined prednisone and cydophos-
phamide // N. Engl. J. Med. - 1978. -
Vol.299.-P. 1151-1155.

47. Donadio J.V., Holley K.E., Wagoner
R.D. et al.
Treatment of lupus nephritis with
prednisone and combined prednisone and
azathioprine //Ann. Intern. Med. — 1972.
- Vol. 77. - R 829-835.

48. Dooley M.A., Cosio F.G., Nachman P.
et al.
Mycophenolate mofetil therapy in lu­
pus nephritis: Clinical observations //
J. Am. Soc. Nephrol. - 1999. - Vol. 10. -
R833.

49. Dubois EL. Letter: Ibuprofen for sys­
temic lupus erythematosus // N. Engl. J.
Med. - 1975. - Vol. 293. - P. 779.

50. EulerH.H., SchroederJ.O., Harten P. et
al.
Treatment-free remission in severe sys­
temic lupus erythematosus following syn­
chronization of plasmapheresis with sub­
sequent pulse cyclophosphamide// Arthritis
Rheum. - 1994. - Vol. 37. - P. 1784.

51. Felson D. T., Anderson J. Evidence for the
superiority of immunosuppressive drugs and
prednisone over prednisone alone in lupus
nephritis//N. Engl. J. Med. - 1984. -Vol.
311. -P. 1528-1533.

 

52. Flanc R.S., Roberts M.A., Strippoli
G.F.M. et al.
Treatment for lupus nephri­
tis //The Cochrane Library. - 2004. - Is. 2.

53. Fleming H.G. et al. Bullous systemic
lupus erythematosus // Int. J. Dermatol. —
1989. -Vol.28. - P. 321-326.

54. Fu L.W., YangLY., Chen W.P., Lin C.Y.
Clinical efficacy of cyclosporin A neoral in the
treatment of pediatric lupus nephritis with
heavy proteinuria // Br. J. Rheumatol. -
1998:.-Vol. 37. -P. 217-221.

55. Fucuda M., Kamiyama Y., Kawahara K.
et al.
The favorable effect of cyclophos­
phamide pulse therapy in the treatment of
massive pulmonary haemorrhage in systemic
lupus erythematosus // Eur. J. Paediatr. —
1994. -Vol. 153. - P. 167-170.


56. Galindo-Rodriguez G., Avlna-Zubieta
J.A., Pizarro S. et al.
Cyclophosphamide
pilse therapy in optic neuritis due to systemic
lupus erythematosus: an open trial //Am. J.
Med. - 1999. - Vol. 106, N 1. - P. 65-69.

57. George J.N., WoolfS.H., Raskob G.E. et
al.
Idiopathic thrombocytopenic purpura: A
practice guideline developed by explicit
methods for the American Society of Hema-
tology// Blood. - 1996. - Vol. 88. - P. 3.

58. GinsbergJ.S., WeltsP.S.. Brill-Edwards
P. et at.
Antiphospholipid antibodies and
venous thromboembolism // Ibid. - 1995.

- Vol. 86. - P. 3685.

59. Glicklich D., AcharyaA. Mycophenolate
mofetil therapy for lupus nephritis refractory
to intravenous cyclophosphamide // Am. J.
Kidney Dis. - 1998. - Vol. 32. - P. 318.

60. Ginzler E., Diamond H., Guttadauria
M., Kaplan D.
Prednisone and azathioprine
compared to prednisone plus low dose azathi-
oprine and cyclophosphamide in the treat­
ment of diffuse lupus nephritis // Arthritis
Rheum. - 1976. - Vol. 19. - P. 693-699.

61. GoebelK.M., Gassel W.D., Goebel F.D.
Evaluation of azathioprine in autoimmune
thrombocytopenia and lupus erythematosus
// Scand. J. Haematol. - 1973. - Vol. 10.

- P. 28.

62. Goldstein £., Carey W. Discoid lupus
erythematosus: successful treatment with
oral methotrexate // Arch. Dermatol. -
1994. - Vol. 130. - P. 938-939.

63. Gourley M.F., Austin H.A., Scott D. et
al.
Methylprednisolone and cyclophos­
phamide alone or in combination in patients
with lupus nephritis//Ann. Intern. Med. -
1996.-Vol. 125.-P. 549-557.

64. Hahn B.V., Kantor O.S., Osterland C.K.
Azathioprine plus prednisone compared with
prednisone alone in the treatment of systemic
lupus erythematosus //Ibid. — 1975. —Vol.
83. - R 597-605.

65. Hellmann D.B.. Petri M., Whiting-
O'Keefe Q.
Fatal infections in systemic lupus
erythematosus: the role of opportunistic
organisms//Medicine (Baltimore). - 1987.
-Vol.66. -P. 341-348.

66. Hirsh J.. Fuster V., AnsellJ.. Halperin
J.L.
American Heart Association/American


Системная красная волчанка о- 163

College of Cardiology Foundation Guide to warfarin therapy // Circulation. - 2003. -Vol. 107. -P. 1692-1711.

67. Hochberg M.C. Updating the American
College of Rheumatology revised criteria for
the classification of systemic lupus erythe­
matosus. [Letter] // Arthritis Rheum. -
1997.-Vol.40.-P. 1725.

68. Houssiau F.A., Vasconcetos C., D'Cruz
D. et al.
Immunosuppressive therapy in lu­
pus nephritis // ibid. - 2002. - Vol. 46. -
P. 2121-2131.

69. Illei G.G., Austin H.A., Crane M. et al.
Combination therapy with pulse cyclo­
phosphamide plus pulse methylprednisolone
improves long term renal outcome without
adding toxicity in patients with lupus
nephritis // Ann. Intern. Med. - 2001. -
Vol. 135. - P. 248-2457.

70. Illei G.G.. Takada K., Parkin D. et al.
Renal flares are common in patients with
severe proliferative lupus nephritis treated
with pulse immunosuppressive therapy //
Arthritis Rheum. - 2002. - Vol. 46. -
P. 995-1002.

71. loannou Y., Isenberg D.A. Current
concepts for the management of systemic
lupus erythematosus in adults: a therapeutic
challenge // Postgrad. Med. J. - 2002. -
Vol. 78. - P. 599-606.

72. Jacob H.S. Pulse steroids in hematologic
diseases // Hosp. Pract. (Off. Ed.) - 1985.
- Vol. 20. - P. 87.

73. Jessop S., Whitelaw D., Jordaan F.
Drugs for discoid lupus eryhtematosus //
The Cochrane Library. - 2004. - Is. 2.

74. Kashgarian M. Lupus nephritis:
pathology, pathogenesis, clinical correla­
tions, and prognosis // Dubois' Lupus
Erythematosus. - 2002. - P. 1061-1076.

75. Khamashta M.A., Cuadrado M.J.. Mu-
jic F. et al.
The management of thrombosis
in the antiphospholipid-antibody syndro­
me//N.Engl.J. Med. - 1995.-Vol.332. -
R993.

76. Kolasinski S.L, Chung].В., Albert D.A.
What do we know about lupus membra­
nous nephropathy? An analytic review //
Arthritis Care Res. - 2002. - Vol. 47. -
R 450-455.


164Ревматология ♦ Системная красная волчанка


77. Kovacs В., Lafferty T.L., Brent L.H.,
DeHoratius R.J.
Transverse myelopathy in
systemic lupus erythematosus: An analysis
of 14 cases and review of the literature //
Ann. Rheum. Dis. - 2000. - Vol. 59. - R 120.

78. Levy Y., Sherer Y., George J. et al.
Intravenous immunoglobulin treatment of
lupus nephritis // Semin. Arthritis Rheum.

- 2000. - Vol. 29. -P. 321.

79. Levy R.A., Vilela V.S., Cataldo M.J. et
al.
Hydroxychloroquine (HCQ) in lupus
pregnancy: double-blind and placebo-
controlled study // Lupus. - 2001. - Vol.
10. -P. 401-404.

80. Lewis E.J., Hunsicker L.G., Lan S. et al.
A controlled trial of plasmapharesis therapy
in severe lupus nephritis // N. Engl. J. Med.

- 1992. - Vol. 326. - P. 1373-1379.

81. Liebling M.R., McLaughlin K., Boonsue
S. et al.
Monthly pulses of methylpred-
nisolone in SLE nephritis // J. Rheumatol.

- 1982. - Vol. 9. - P. 543-548.

82. Lockshin M.D., Sammarltano L.R.
Lupus pregnancy //Autoimmunity. —2003. —
Vol. 36. - P. 33.

83. Maier W.P., Gordon D.S., Howard R.F.
et al.
Intravenous immunoglobulin therapy
in systemic lupus erythematosus-associated
thrombocytopenia // Arthritis Rheum. —
1990. -Vol.33. - P. 1233.

84. Malaviya A.N., Mourou M. Should low-
dose aspirin also be a background therapy for
all patients with systemic lupus erythema­
tosus // Lupus. - 2000. - Vol. 9. - P. 561 -
562.

85. Manzi S., Meilahn E.N., Ralrie J.E. et
al.
Age specific incidence rates of myocardial
infarction and angina in women with sys­
temic lupus erythematosus: comparison with
the Framingham study // Am. J. Epide­
miol. - 1997. - Vol. 145. - P. 408-415.

86. Meinao I.M., Sato E., Andrade LE.G.
et al.
Controlled trial with chloroquine di-
phosphate in systemic lupus erylhemalosus
//Lupus.- 1996.-Vol. 5.-R 237-241.

87. Mok C.C., Ho C, Siu Y.P. et al.
Treatment of diffuse lupus glomeruloneph-
ritis: a comparison of two cydophos-phamide
containing regimens//Am. J. Kidney Dis. -
2001. -Vol.38. - P. 256-264.


 

88. Мое C.C., Но СТ., Chan K.W. et al.
Outcome and prognostic indicators of diffuse
proliferative lupus glomerulonephritis treated
with sequential oral cyclophosphamide and
azathioprine//Arthritis Rheum. - 2002. -
Vol.46. -P. 1003.

89. Mok C.C, Ying K.Y., Tang C.W. et al.
Role of azathioprine in the prevention of renal
relapses after successful cyclophosphamide
induction of diffuse proliferative lupus glome­
rulonephritis [abstract] // Ibid. - Suppl. -
R S289.

90. Mok C.C, Lau C.S., Chan E.Y., Wong
R.W.
Acute transverse myelopathy in
systemic lupus erythematosus: Clinical
presentation, treatment, and outcome //
J. Rheumatol. - 1998. - Vol. 25. - P. 467.

91. Moore P.M., Cupps T.R. Neurological
complications of vasculitis//Ann. Neurol. -
1983. - Vol. 14. - P. 55.

92. Murphy S., LoBuglio A.F. Drug therapy
of autoimmune hemolytic anemia // Semin.
Hematol. - 1976. - Vol. 13. - P. 323.

93. Neuwelt СМ., Lakes S., Kaye B.R. et al.
Role of intravenous cyclophosphamide in the
treatment of severe neuropsychiatric sys­
temic lupus erythematosus // Am. J.
Med. - 1995. - Vol. 98. - P. 32.

94. Nossent H.C., Koldingsnes W. Long-
term efficacy of azathioprine treatment for
proliferative lupus nephritis // Rheumatology
(Oxford). - 2000. - Vol. 39. - R 969.

95. Parke A.L. Antimalarial drugs, systemic
lupus erythermatosus and pregnancy //
J. Rheumatol. - 1988. - Vol. 15. - R 607-
610.

96. Parke A.L., West B. Hydroxychloroquine
in pregnant patients with systemic lupus
erythematosus // Ibid. - 1996. - Vol. 23. -
P. 1715-1718.

97. Petri M.A., Lahita B.G., van Vollen-
hoven R.F. et al.
Effects of prasterone on
corticosteroid requirement of women with
systemic lupus erythematosus: a double-
blind, randomized, placebo-controlled tri­
al // Arthritis Rheum. - 2002. - Vol. 46. -
R 1820-1829.

98. Petersen H.H., Nielsen H., Hansen M.
et al.
High dose immunoglobulin therapy in
peroicarditis caused by SLE // Scand.


J. Rheumatol. - 1990. - Vol. 19. -P. 91-93.

99. Petri M. Mycophenolate mofetil
treatment of SLE // Arthritis Rheum. -
1999. - Vol. 42. - Suppl. - P. S303.

100. Petri M.,AllbrittonJ. Antibiotic allergy
in systemic lupus erythematosus: a case-
control study//J. Rheumatol. - 1992. -
Vol. 19. - P. 265-269.

 

101. Petri M., Spence D., Bone L.R.,
Hochberg M.C.
Coronary artery disease risk
factors in the Johns Hopkins Lupus Cohort:
prevalence, recognition by patients, and
preventive practices // Medicine (Balti­
more). - 1992. -Vol.71. -P. 291-302.

102. Pohl M.A., Lan S., Bed T. et al.
Plasmapharesis does not increase the risk for
infection in immunosuppressed patients
with severe lupus nephritis // Ann. Intern.
Med. - 1991. -Vol. 114. - P. 924-929.

103. Quismorio F.P.Jr. Hematologic and
lymphoid abnormalities in systemic lupus
erythematosus // Dubois' Lupus Erythe­
matosus. - 2002. - P. 793-819.

104. RadhakrishnanJ., Kunis C.L, D'Agati
V., Appel G.B.
Cyclosporine treatment of
lupus membranous nephropathy // Clin.
Nephrol. - 1994. - Vol. 42. - P. 147.

105. Rahman P., Humphrey-Murto S.,
Gladman D.D., Urowitz M.B.
Efficacy and
tolerability of methotrexate in antimalarial
resistant lupus arthritis // J. Rheumatol. -
1998.-Vol.25. -R243.

106. Ramos P.C., Mendez M.J., Ames P.R.
et al.
Pulse cyclophosphamide in the
treatment of neuropsychiatric systemic lupus
erythematosus // Clin. Exp. Rheumatol. -
1996.-Vol. 14.-P. 295.

107. Rock G.A., Shumack K.H., Buscard
N.A. et al.
Canadian Apheresis Study gro­
up. Comparison of plasma exchange with
plasma infusion in the treatment of throm-
botic thrombocytopenic purpura // N. Engl.
J. Med. - 1991. - Vol. 325. - P. 393-
397.

108. Rosove M.H., Brewer P.M.
Antiphospholipid thrombosis: Clinical cour­
se after the first thrombotic event in 70
patients // Ann. Intern. Med. - 1992. -
Vol. 117. - P. 303.


Системная красная волчанка «■ 165

109. Ruiz-lrastorza G., Khamashta M.A.,
Hughes G.R.V.
Antiagregant and
anticoagulant therapy in systemic lupus
erythematosus and Hughes syndrome //
Lupus. - 2001. - Vol. 10. - P. 241-245.

110. RundD., Schaap Т., Gillis S. Intensive
plasmapheresis for severe thrombotic throm­
bocytopenic purpura: long-term clinical
outcome // J. Clin. Apheresis. — 1997. -
Vol. 12.-P. 194-195.

111. Sammaritano L. Update on the ma­
nagement of the pregnant patients with
antiphospholipid antibody // Curr. Rheu­
matol. Rep. - 2001. - Vol. 3. - P. 213-
221.

112. Sanchez-Guerrero J., Karlson E.W.,
Liang M.H. et al.
Past use of oral contra­
ceptives and the risk of developing systemic
lupus erythematosus // Arthritis Rheum. -
1997.-Vol. 40. -P. 804-808.

113. Sanchez-Guerrero J., Liang M.H.,
Karlson E. W. et al.
Postmenopausal estrogen
therapy and the risk for developing systemic
lupus erythematosus // Ann. Intern. Med.

- 1995. - Vol. 122. - R 430-433.

114. Scott J.R., Branch W.D., Kochenour
N.K. Ward K.
Intravenous immunoglobulin
treatment of pregnant patients with recurrent
pregnancy loss caused by antiphospho­
lipid antibodies and Rh immunization //Am.
J. Obstet. Gynecol. - 1988. - Vol. 159. -
P. 1055.

115. Sesso R., Monteiro M., Sato E. et al. A
controlled trial of pulse cyclophosphamide
versus pulse methylprednisolone in severe
lupus nephritis // Lupus. - 1994. - Vol. 3.
-R 107-112.

116. Schnabel A., Reuter M., Gross W.L.
Intravenous pulse cyclophosphamide in the
treatment of intersticial lung disease due to
collagen vasculardiseases//Arthritis Rheum.

- 1998. - Vol. 41. - R 1215-1220.

117. SimmsR.W., AndersonJJ., ZebriniA.,
Felson D.T.
Treatment of glucocorticoid-
induced osteoporosis: a meta-analysis
[Absract] // Ibid. - 1993. - Vol. 36. N 9. -
Suppl. - P. S50.

118. Spinnato J.A., Clark A.L., Pierangeli
S.S., Harris E.N.
Intravenous immuno­
globulin therapy for the antiphospholipid


166 о Ревматология о Системная красная волчанка


syndrome in pregnancy // Am. J. Obstet. Gynecol. - 1995. - Vol. 172. - P. 690.

119. Steinberg A.D., Steinberg S.C. Long
term preservation of renal function in patients
with lupus nephritis receiving treatment that
includes cyclophosphamide versus those
treated with prednisone only // Arthritis
Rheum. - 1991. - Vol. 34. - P. 945-950.

120. Steinberg A.D., Decker J.L A double
blind controlled trial comparing cyclo­
phosphamide, azathioprine and placebo in
the treatment of lupus glomerulonephritis
// Ibid. - 1974. - Vol. 17. - P. 923-937.

121. Steinberg A.D., Kaltreider H.B.,
Staples P.J. et al.
Cyclophosphamide in
lupus nephritis: a controlled trial // Ann. In­
tern. Med. - 1971.-Vol. 75. -R 165-171.

122. Stojanovich L., Stojanovich R., Kos-
tich V., Dzjolich E.
Neuropsychiatric lupus
favourable response to low dose i.v.
cyclophosphamide and prednisolone (pilot
study)//Lupus. - 2003. - Vol. 12. - P. 3.

123. Strand V., Gladman D., Isenberg D.
Endpoints: consensus recommendations
from OMERACT IV // Ibid. - 2000. -
Vol. 9. - P. 322-327.

124. Sugiyama M., Ogasawara H., Kane-
ko H. et al.
Effect of extremely low dose
cyclosporine treatment on the thrombo-
cytopenia in systemic lupus erythematosus
// Lupus. - 1998. - Vol. 7, N 1. - P. 53-56.

125. Sztejnbok M., Stewart A., Diamond
H., Kaplan D.
Azathioprine in the treatment
of systemic lupus erythematosus // Arthritis
Rheum. - 1971. - Vol. 14. - P. 639-645.

126. Tarn L.S., Li E.K., Leung C.B. et al.
Long-term treatment of lupus nephritis with
cyclosporinA//QJM. - 1998. -Vol.91. -
R573.

127. TamE.M., Cohen A.S., Fries J.F. et al.
The 1982 revised criteria for the classification
of systemic lupus erythematosus // Arthritis
Rheum. - 1982. - Vol. 25. - P. 1271-
1277.

128. The Canadian Hydroxychloroguine
Study Group. A randomized study of the
effect of withdrawing hydroxychloroquine
suifate in systemic lupus erythematosus //
N. Engl. J. Med. - 1991. - Vol. 324. -
P. 150-154.


129. The Canadian Hydroxychloroquine
Study Group. A long-term study of
hydroxychloroquine withdrawal on exa­
cerbations in systemic lupus erythematosus
// Lupus. - 1998. - Vol. 7. - P. 80-85.

130. Trevisani V.F.M., Castro A.A.,Neto J.F.
et al.
Cyclophosphamide versus methyl-
prednisolone for treating neuropsychiatric
involvement in systemic lupus erythematosus
// The Cochrane Library. - 2004. - Is. 2.

131. Uramoto KM., Michet C.J., Thumbo
J. et al.
Trends in the incidence and mortality
of systemic lupus erythematosus, 1950—
1992 // Arthritis Rheum. - 1999. -
Vol. 42. - P. 46-50.

132. van Vollennoven R., Engleman E.G.,
McGuire J.L.
Dehydroepiandrosterone in
systemic lupus erythematosus results of a
double-blind, placebo-controlled, rando­
mized clinical trial // Arthritis Rheum. —
1995. - Vol. 38. - P. 1826-1831.

133. van Vollenhoven R.F., Park J.L.,
Genovese U.C. et al.
A double-blind,
placebo-controlled clinical trial of de­
hydroepiandrosterone in severe systemic
lupus erythematosus // Lupus. - 1999. -
Vol.8.-P. 181-187.

134. Van Vollenhoven H.F.
Denydroepiandrosterone in systemic lupus
erythematosus // Rheum. Dis. Clin. North
Am. - 2000. - Vol. 26. - P. 349-62.

135. Van Vollenhoven R.F., Elliott £>.,
Powell M. et al. Dehydroepiandrosterone
improves cognitive function in patients with
systemic lupus erythematosus-results of
double blind placebo controlled pilot study//
Arthritis Rheum (Abstracts). — 2001.
P. 26.

136. Wachl D.G., Bounameaux H., de
Moerloose P., Sarasin F.P.
Prophylactic
antithrombotic therapy for patients with sys­
temic lupus erythematosus with or without
antiphospholipid antibodies//Arch. Intern.
Med. - 2000. - Vol. 160. - P. 2042-2048.

137. WallaceDJ., GoldfingerD.,Pepkowitz
S.H. et al.
Randomized controlled trial of
pulse/synchronization cyclophopsphamide
apheresis for proiiferativ.e lupus nephritis //
J. Clin. Apheresis. - 1998. - Vol. 13. -
P. 163-166.


138. Wallace D.J. Antimalarial agents and
lupus // Rheum. Dis. Clin. North Am. -
1994.-Vol. 20.-P. 243.

139. Wallace D.J., Hahn B.H., KlippelJ.N.
Clinical and laboratory features of lupus
nephtiris // Dubois' Lupus Erythemato-
sus. -2002. -P. 1077-1091.

140. Weitz J.I. Low-molecular-weight
heparins // N. Engl. J. Med. - 1997. -
Vol. 337. - P. 688-698.

141. Williams H.J., Egger MJ., Singer J.I.
et al.
Comparison of hydroxychloroquine
and placebo in the treatment of the arthro-
pathy of mild systemic lupus erythemato-
sus // J. Rheumatol. - 1994.Vol. 21.
P. 1457-1462.

142. Wilson K., Abeles M. A 2-year, open
ended trial of methotrexate in systemic lupus
erythematosus // Ibid. - P. 1674.


Системная красная волчанка167

143. Yoon K.H. Sufficient evidence to
consider hydroxychloroquine as an adjunct
therapy in antiphospholipid antibody
(Hughes') syndrome // Ibid. - P. 2002.

144. Иванова М.М. Системная красная
волчанка //Диффузные болезни соедини­
тельной ткани. - М.: Медицина, 1994. -
С. 231-301.

145. Насонов Е.Л. Антифосфолипидный
синдром. — М.: Литера, 2004.

146. Насонов Е.Л. Противовоспалитель­
ная терапия ревматических болезней. -
М.: М-Сити, 1996.

147. Соловьёв С.К. Лечение ревматичес­
ких болезней ударными дозами метипреда
(пульс-терапия). - М.: Мик, 1999.

148. Соловьёв С.К. Интенсивная терапия
ревматических болезней. Пособие для вра­
чей. -М.: Мик, 2001.


СИСТЕМНАЯ СКЛЕРОДЕРМИЯ


Системная склеродермия — аутоиммун­ное заболевание соединительной ткани, основные клинические признаки которо­го обусловлены распространёнными на­рушениями микроциркуляции, фибро­зом кожи и внутренних органов. Системная склеродермия — важнейший представитель склеродермической груп­пы болезней, к которым также относят­ся ограниченная (очаговая)склеродер­мия, диффузный эозинофильный фасци-ит, склередема Бушке, мультифокаль-ный фиброз, индуцированные формы склеродермии и псевдосклеродермичес-кие синдромы.

МКБ-10: М34 Системный склероз; М34.0 Прогрессирующий системный склероз; М34.1 Синдром CREST; M34.2 Системный склероз, вызванный лекар­ственными средствами и химическими соединениями; М34. 8 Другие формы си­стемного склероза.

Аббревиатуры: ССД — системная скле­родермия; ИЗЛ — интерстициальное заболевание лёгких.

ЭПИДЕМИОЛОГИЯ11

• Распространённость ССД различает­
ся между отдельными географически­
ми зонами и этническими группами, в
том числе проживающими в одном ре­
гионе.

• Первичная заболеваемость колеблет­
ся от 3,7 до 19,0 на 1 млн населения
в год.

• ССД чаще встречается у женщин (со­
отношение 5—7 к 1) в возрасте 30—
60 лет.

Профилактика не проводится. Скрининг не проводится.


Дата добавления: 2015-10-20 | Просмотры: 622 | Нарушение авторских прав







При использовании материала ссылка на сайт medlec.org обязательна! (0.044 сек.)